News

Press Release | Jun 18, 2020

Nutrition21, LLC (“Nutrition21“) has announced the conclusion of a dispute with MythLabs following MythLabs’ agreement to cease any further intellectual property (IP) infringement of Nutrition21’s ingredient Nitrosigine®. Nutrition21 discovered a product being sold in the marketplace, MythLabs Pump, that claimed to include the powerful NO booster Nitrosigine without a purchase and trademark license agreement. Upon

News | Jun 12, 2020

The difficulty of raising that maiden fund emerged as a recurring theme in my conversations these past few weeks with five women founders who have done it–Jeri Harman of Avante Capital, JoAnn Price of Fairview Capital Partners (pictured), Hollie Haynes of Luminate Capital Partners, Kristina Heinze of ParkerGale, and Adele Oliva of 1315 Capital.

Press Release | May 21, 2020

Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) is pleased to announce the closing of its previously announced public offering (the “Offering”) of common shares of the Company (the “Offered Shares”). The Offering was made pursuant to an agency agreement (the “Agency Agreement”) entered into among Bloom Burton Securities Inc. and Clarus Securities Inc.,

Press Release | May 05, 2020

Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX: GTMS) announced today that it has filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, pursuant to National Instrument 44-101 Short Form Prospectus Distributions, in connection with a proposed

Press Release | Apr 28, 2020

Innovative Health, Inc. today announced the availability of three new informational web sessions, being held in early May, to help fill the learning gap left by the cancellation of this year’s Heart Rhythm Scientific Sessions. These sessions will educate administrators and clinicians on new and emerging opportunities for cost reductions through the reprocessing of advanced EP devices.

Press Release | Apr 28, 2020

Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions (Avalon), a specialty benefit management company with more than 3 million members, focused on laboratory testing. The new contract, whose terms were not disclosed, includes two of the Southeastern U.S.’s largest Blue Cross Blue Shield

Pages 1 2 3 4 15